ourlyard glp 1 oral Head-to-head trial shows Eli Lilly's GLP-1 orforglipron outperforms oral semaglutide Moving (beyond) the needle: Everything
Description
Even at lower doses, GLP-1 receptor agonists may provide powerful health benefits
Although these drugs share a common mechanism, individual responses can vary
Sources: GoodRx and CNN
Find out more about the alliance at www.boehringer-ingelheim.com or www.lilly.com
As central insulin resistance appears to be a risk factor for neurodegenerative disorders, these analogues might provide interesting avenues to protect against neurodegeneration and conditions such as Alzheimers and Parkinsons disease
